http://rdf.ncbi.nlm.nih.gov/pubchem/patent/IE-33848-B1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f88f84fc279fe5d0b9b5ec3c88c2e2b2
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G06Q20-047
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D317-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D211-32
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D317-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-62
filingDate 1969-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b3b9979b67ac0dfe7af256ea7ee0d8fc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b15b9548a92c7c32879a719ee93ffc94
publicationDate 1974-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber IE-33848-B1
titleOfInvention 3-(-4)-aroylpiperidines
abstract 1,268,909. Aroyl-piperidines. A. H. ROBINS CO. Inc. 18 June, 1969 [20 June, 1968], No. 30871/69. Heading C2C. Novel compounds of the formula where R denotes acetyl, aryl, carbamoyl, NC 1-8 alkylcarbamoyloxy, carbamoyloxy, aryloxy, aroyl, ethoxy, 4-phenyl-1-piperazinylacetyl, NC 1-8 -alkylcarbamoyl, N,N-di(C 1-8 alkyl)carbamoyl, N-arylthiocarbamoyl, N-arylcarbamoyl, carbethoxy or 2,3-dihydroxypropyl; R<SP>1</SP> denotes H, F, Cl, Br, C 1-8 alkyl, C 1-8 alkoxy or CF 3 ; Y denotes -CH 2 - and n is 0, or 1-4, and acid addition salts thereof, may be obtained by the steps of (1) reacting nipecotic acid or isonipecotic acid with a lower acyl anhydride to form a 1- lower acyl nipecotic or isonipecotic acid, (2) reacting the latter with thionyl halide to form the corresponding acid halide, (3) reacting the product with an aryl compound in the presence of an aluminium trihalide to give a 1-lower acyl- 3- or 4-aroylpiperidine, (4) hydrolysing to form a 3- or 4-aroyl piperidine, (5) reacting the product with an arylalkyl halide, aryloxyalkyl halide, aroylalkyl halide, #-hydroxyalkyl halide, 4- phenyl-1-piperazinyl acetyl chloride, C 1-8 alkyl isocyanate, N,N-di(C 1-8 alkyl) carbamoyl halide, arylisothiocyanate, arylisocyanate, ethyl chloroformate, 2,3-dihydroxypropyl halide, nitrourea, sodium cyanate or 2-bromoethyl ethyl ether; and where an #-hydroxyalkyl halide is used, (6) reacting the 1-(#-hydroxyalkyl)-4-aroylpiperidine with a C 1-8 alkyl isocyanate. 4-Aroylpiperidines may also be obtained by the steps: (1) dehydrating 1-acetyl-4-carbamoylpiperidine to 1-acetyl-4-cyanopiperidine, (2) reacting the product with an arylmagnesium halide to give a 1-acetyl-4-aroylpiperidine, (3) hydrolysing in an acidic medium to give a 4-aroyl-piperidine and reacting the latter as in (5) above. A further preparation of 4-aroyl-piperidines comprises reacting under cyclizing conditions using NaH a γ-[N-(2-haloethyl)-N-substituted]-amino butyrophenone of Formula X Intermediates are prepared by reacting ethanolamine with 2-(p-fluorophenyl)-2-(3-chloropropyl)-1,3-dioxolane to yield 2-(p-fluorophenyl)- 2 - [3 - N - (2 - hydroxyethyl)aminopropyl]- 1,3- dioxolane, reacting this with 2-(o-methoxyphenoxy) ethyl bromide to give p-fluoro-γ[N-2- hydroxyethyl - N - 2 - (o - methoxyphenoxy)- ethyl]-aminobutyrophenone which is acidified with HCl and then reacted with SOCl 2 to form pfluoro - γ - [N - (2 - chloroethyl) - N - (2 - omethoxyphenoxyethyl)amino]butyrophenone hydrochloride. Pharmaceutical compositions useful as tranquillizing agents comprise compounds of Formula I above and a pharmaceutically acceptable carrier, preferably in the form of tablets or soft gelatine capsules.n[GB1268909A]
priorityDate 1968-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID453278078
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID86676953
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419483691
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID18474173
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2723778
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID416168317
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419491804
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419573487
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID455824109
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419494814
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID62372
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458396411
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419519841
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID430824729
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5359268
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458396401
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393598
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID53627726
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1799099
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3773
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393768
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID517096
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID423390483
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419544143
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID20088731
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4498
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID700
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393349
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID413709382
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID416134510
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID61141
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID420117036
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393641
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2756286
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID416149893

Total number of triples: 51.